These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 10565232)

  • 1. [Factor IX inhibitor in hemophilia B presented with anaphylactoid symptoms: report of 3 cases].
    Taketani T; Hanada R; Kawaguchi H; Ida K; Yamamoto K
    Rinsho Ketsueki; 1999 Oct; 40(10):1124-6. PubMed ID: 10565232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction.
    Curry NS; Misbah SA; Giangrande PL; Keeling DM
    Haemophilia; 2007 May; 13(3):328-30. PubMed ID: 17498084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis.
    Alexander S; Hopewell S; Hunter S; Chouksey A
    J Pediatr Hematol Oncol; 2008 Jan; 30(1):93-5. PubMed ID: 18176193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
    Parquet A; Laurian Y; Rothschild C; Navarro R; Guérois C; Gay V; Durin A; Peynet J; Sultan Y
    Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies to factor IX.
    Warrier I
    Haematologica; 2000 Oct; 85(10 Suppl):31-3; discussion 33-4. PubMed ID: 11187867
    [No Abstract]   [Full Text] [Related]  

  • 6. Failure of immunosuppression in a severe haemophilia B patient with specific antibody.
    Allain JP; Frommel D
    Thromb Haemost; 1976 Aug; 36(1):86-9. PubMed ID: 1036830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX.
    Barnes C; Davis A; Furmedge J; Egan B; Donnan L; Monagle P
    Haemophilia; 2010 Sep; 16(5):840-1. PubMed ID: 20546030
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B.
    Shapiro AD; Ragni MV; Lusher JM; Culbert S; Koerper MA; Bergman GE; Hannan MM
    Thromb Haemost; 1996 Jan; 75(1):30-5. PubMed ID: 8713776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of OCTANINE F in children with haemophilia B.
    Klukowska A; Laguna P; Svirin P; Shiller E; Vdovin V
    Haemophilia; 2008 May; 14(3):531-8. PubMed ID: 18355266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor IX alloantibodies shorten the bovine thromboplastin coagulation time of normal human plasma.
    Orstavik KH
    Thromb Haemost; 1981 Dec; 46(4):684-6. PubMed ID: 7330818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
    Mathias M; Khair K; Hann I; Liesner R
    Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis.
    Cugno M; Mancuso ME; Tedeschi A; Santagostino E; Lorini M; Carbonelli V; Peyvandi F; Mannucci PM
    Haemophilia; 2017 Jul; 23(4):e348-e353. PubMed ID: 28594432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate.
    Chuansumrit A; Moonsup Y; Sirachainan N; Benjaponpitak S; Suebsangad A; Wongwerawattanakoon P
    Blood Coagul Fibrinolysis; 2008 Apr; 19(3):208-11. PubMed ID: 18388500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk.
    Thorland EC; Drost JB; Lusher JM; Warrier I; Shapiro A; Koerper MA; Dimichele D; Westman J; Key NS; Sommer SS
    Haemophilia; 1999 Mar; 5(2):101-5. PubMed ID: 10215957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
    Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
    Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 18. A simple inhibitor screen is more sensitive than a Bethesda assay in monitoring for the development of inhibitors in haemophilia A and B.
    Keeling D; Beavis J; Sukhu K
    Br J Haematol; 2005 Mar; 128(6):885. PubMed ID: 15755295
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined factor VIII and IX inhibitors in a non-haemophilic patient: successful treatment with immunosuppressive drugs.
    Carmassi F; Giannarelli C; De Giorgi A; De Negri F
    Haemophilia; 2007 Jan; 13(1):106-7. PubMed ID: 17212735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The successful use of FEIBA for treatment of intracranial hemorrhage in a patient of hemophilia B with inhibitor].
    Taki M; Inagaki M; Tomita Y; Miura T; Saito N; Meguro T; Yamada K
    Rinsho Ketsueki; 1985 Aug; 26(8):1300-5. PubMed ID: 3877831
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.